Navigation Links
BioInformatics, LLC New Report - The Market Outlook for Research Products in FY2010
Date:12/1/2009

ARLINGTON, Va., Dec. 1 /PRNewswire/ -- BioInformatics, LLC announces the release of its newest report, The Market Outlook for Research Products in FY2010. The 8.2 billion dollars appropriated to the NIH Scientific Research program by the American Recovery and Reinvestment Act (ARRA) is being earmarked for lab renovations, Challenge Grants, the Shared Instrumentation Program and research that spans multiple public and non-profit institutions, all of which will have an immediate and long-term impact on the life science tools industry. Comprised of responses from scientists with varying degrees of influence and purchasing authority in the lab, The Market Outlook for Research Products in FY2010 was designed to help provide insight as to how labs are going to allocate their budgets over the next fiscal year, how they are responding to the economic recession and where they believe their organizations are headed in FY2011.

Researchers predict that their FY2010 budgets will, on average, be 4.5% higher than their budgets for FY2009. On the whole, academic respondents foresee slightly larger budget increases (5.5%), while industrial respondents expect somewhat smaller budget increases.

The Market Outlook for Research Products in FY2010, includes detailed responses from nearly 800 scientists about their FY2010 budgets, planned expenditures and sources of funding. This study compares and contrasts FY2009 (actual) and FY2010 (projected) budgets in total, and by product category with a special focus on market segment and regional differences. European and U.S. scientists are asked about planned purchases of both consumables and instrumentation, and from what sources they expect to receive funding, with an emphasis on the ARRA. 61% of the survey respondents said that either they or someone in their lab applied for a recovery act grant.

In this report, scientists also indicate planned instrument and consumable purchases by vendor. The following suppliers were provided as some of the choices in the survey:

Abcam (LSE: ABC.L)

Abgene (Thermo Fisher Scientific ( TMO))

Affymetrix (NasdaqGS: AFFX)

Agilent Technologies

BD Biosciences ( BDX)

Bio-Rad ( BIO)

Beckman Coulter ( BEC)

BioSource (Life Technologies (NasdaqGS: LIFE))

Calbiochem

Millipore ( MIL)

GE Healthcare (Amersham) ( GE)

Invitrogen

Leica Microsystems

PerkinElmer ( PKI)

Qiagen (NasdaqGS: QGEN)

Roche Applied Science

Sigma-Aldrich ( SIAL)

Waters Corporation

"While the overall projections for growth in researchers' FY2010 research budgets are generally positive, differences by geographic region and market segment with respect to funding sources and budget realities will impact not only the spending practices of various labs, but also their receptivity to life science suppliers and their marketing and advertising campaigns," states Tamara Zemlo, Ph.D., MPH, Vice President of Advisory Services. Dr. Zemlo further notes that "Suppliers that are sensitive to a researcher's perceptions of the economy and how it is affecting their science are more likely to maintain good customer relations if they offer promotions that specifically address their customers' concerns."

To learn more about this report, a complimentary Executive Summary is available at http://www.gene2drug.com/reports/205/.

ABOUT BIOINFORMATICS, LLC

BioInformatics, LLC is the premier research and advisory firm serving the life science industry. By leveraging our professional social network of more than 45,000 biomedical researchers, we have supported more than 300 companies and provided insights that lead to better business decisions. Our assignments include assessing the size and attractiveness of markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.



For more information contact:
Mary Follin
Manager, Marketing/Sales
BioInformatics, LLC
2111 Wilson Blvd., Suite 250
Arlington, VA  22201
703.778.3080 x13 (phone)
m.follin@gene2drug.com
http://www.gene2drug.com/


SOURCE BioInformatics, LLC


'/>"/>
SOURCE BioInformatics, LLC
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioInformatics, LLC New Report - Capitalizing on New Opportunities for Stem Cell Products, Now Available
2. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
3. Reportlinker Adds Operating Tables - A World Market Review
4. Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report
5. Reportlinker Adds Europe Ophthalmic Devices Investment Opportunities, Analysis and Forecasts to 2015
6. Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014)
7. Reportlinker Adds Surgical Incision Closures - Global Trends
8. Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review
9. Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective
10. Reportlinker Adds Inflammatory Disorders: Therapies That Suppress or Balance the Immune Response
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... , Dec. 9, 2016   Hudes Laser ... December featuring the multi-wavelength Astanza Trinity laser and ... specializes in laser tattoo removal, IPL hair removal, ... ultrasound therapy. Hudes Laser Aesthetica is setting high ... and promises to deliver effective, long-lasting ...
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... 2016 , ... The Pennsylvania Athletic Trainers’ Society (PATS) aired ... of 2016. The program was made possible by a Pennsylvania Department of Health ... and Human Services Administration. The broadcast, Use Your Head: Properly Managing Sport ...
(Date:12/8/2016)... ... 2016 , ... The Florida Hospital Tampa Wound Healing Institute ... (UHMS), the leading authority in hyperbaric medicine. This accreditation identifies the Institute as ... facilities have earned this distinction. This is the second time the Florida Hospital ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Donuts Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported ... , “This was our first franchise-wide Quack Gives Back initiative, and ...
(Date:12/8/2016)... and JENNERSVILLE, Pa. (PRWEB) , ... December 08, ... ... that Penn Medicine Southern Chester County, a Property owned by an affiliate of ... million, 72,000 square foot Penn Medicine Southern Chester County ambulatory care center (ACC) ...
(Date:12/8/2016)... ... ... CURE Media Group, the nation’s leading digital and print media enterprise focused ... in efforts to combat lung cancer, announced CURE Media Group President Michael J. Hennessy, ... is honored to team up with Upstage Lung Cancer in order to make major ...
Breaking Medicine News(10 mins):